HK1187916A1 - Substituted benzopyrazin derivatives as fgfr kinase inhibitors for the treatment of cancer diseases fgfr - Google Patents
Substituted benzopyrazin derivatives as fgfr kinase inhibitors for the treatment of cancer diseases fgfrInfo
- Publication number
- HK1187916A1 HK1187916A1 HK14101032.2A HK14101032A HK1187916A1 HK 1187916 A1 HK1187916 A1 HK 1187916A1 HK 14101032 A HK14101032 A HK 14101032A HK 1187916 A1 HK1187916 A1 HK 1187916A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- fgfr
- benzopyrazin
- derivatives
- substituted
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41774410P | 2010-11-29 | 2010-11-29 | |
| GBGB1020179.6A GB201020179D0 (en) | 2010-11-29 | 2010-11-29 | New compounds |
| PCT/GB2011/052356 WO2012073017A1 (en) | 2010-11-29 | 2011-11-29 | Substituted benzopyrazin derivatives as fgfr kinase inhibitors for the treatment of cancer diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1187916A1 true HK1187916A1 (en) | 2014-04-17 |
Family
ID=43500774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK14101032.2A HK1187916A1 (en) | 2010-11-29 | 2014-01-30 | Substituted benzopyrazin derivatives as fgfr kinase inhibitors for the treatment of cancer diseases fgfr |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US9290478B2 (pt) |
| EP (1) | EP2646432B1 (pt) |
| JP (1) | JP5868992B2 (pt) |
| KR (1) | KR101914720B1 (pt) |
| CN (1) | CN103370314B (pt) |
| AU (1) | AU2011334624B2 (pt) |
| BR (1) | BR112013013435B1 (pt) |
| CA (1) | CA2819009C (pt) |
| DK (1) | DK2646432T3 (pt) |
| ES (1) | ES2541493T3 (pt) |
| GB (1) | GB201020179D0 (pt) |
| HK (1) | HK1187916A1 (pt) |
| HR (1) | HRP20150692T8 (pt) |
| HU (1) | HUE025091T2 (pt) |
| MX (1) | MX2013005897A (pt) |
| RU (1) | RU2602233C2 (pt) |
| SI (1) | SI2646432T1 (pt) |
| SM (1) | SMT201500191B (pt) |
| WO (1) | WO2012073017A1 (pt) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| GB201020179D0 (en) * | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
| US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| WO2013032951A1 (en) | 2011-08-26 | 2013-03-07 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| EP2755657B1 (en) | 2011-09-14 | 2017-11-29 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| US9249110B2 (en) | 2011-09-21 | 2016-02-02 | Neupharma, Inc. | Substituted quinoxalines as B-raf kinase inhibitors |
| US9249111B2 (en) * | 2011-09-30 | 2016-02-02 | Neupharma, Inc. | Substituted quinoxalines as B-RAF kinase inhibitors |
| GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
| GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118652D0 (en) * | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| US9670180B2 (en) | 2012-01-25 | 2017-06-06 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| GB201209609D0 (en) * | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| PT3176170T (pt) | 2012-06-13 | 2019-02-05 | Incyte Holdings Corp | Compostos tricíclicos substituídos como inibidores de fgfr |
| WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
| EP2897618B1 (en) | 2012-09-24 | 2021-11-17 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| WO2014044846A1 (en) | 2012-09-24 | 2014-03-27 | Evotec (Uk) Ltd. | 3-(aryl- or heteroaryl-amino)-7-(3,5-dimethoxyphenyl)isoquinoline derivatives as fgfr inhibitors useful for the treatment of proliferative disorders or dysplasia |
| WO2014075077A1 (en) | 2012-11-12 | 2014-05-15 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| AR094812A1 (es) | 2013-02-20 | 2015-08-26 | Eisai R&D Man Co Ltd | Derivado de piridina monocíclico como inhibidor del fgfr |
| SG10201708520YA (en) | 2013-04-19 | 2017-12-28 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| GB201307577D0 (en) * | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
| EP2924038A1 (en) | 2014-03-24 | 2015-09-30 | Evotec (UK) Ltd. | Preparation of pyrrolo[2,3-b]pyrazine and pyrrolo[2,3-b]pyridine derivatives as FGFR inhibitors |
| JO3512B1 (ar) * | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
| KR102479693B1 (ko) | 2014-03-26 | 2022-12-22 | 아스텍스 테라퓨틱스 리미티드 | 조합물 |
| WO2015144808A1 (en) | 2014-03-26 | 2015-10-01 | Astex Therapeutics Ltd | Combinations of an fgfr inhibitor and an igf1r inhibitor |
| MX369646B (es) | 2014-08-18 | 2019-11-15 | Eisai R&D Man Co Ltd | Sal de derivado de piridina monociclico y su cristal. |
| CN113957146A (zh) * | 2014-09-26 | 2022-01-21 | 詹森药业有限公司 | 使用fgfr突变基因组鉴定将对用fgfr抑制剂进行治疗有反应的癌症患者 |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
| WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| TWI712601B (zh) | 2015-02-20 | 2020-12-11 | 美商英塞特公司 | 作為fgfr抑制劑之雙環雜環 |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| WO2017017516A1 (en) * | 2015-07-24 | 2017-02-02 | Debiopharm International Sa | Fgfr expression and susceptibility to an fgfr inhibitor |
| KR20180052623A (ko) | 2015-09-23 | 2018-05-18 | 얀센 파마슈티카 엔.브이. | 신규 화합물 |
| RU2747644C2 (ru) * | 2015-09-23 | 2021-05-11 | Янссен Фармацевтика Нв | Бигетероарил-замещенные 1,4-бензодиазепины и пути их применения для лечения рака |
| EP3365335B1 (en) | 2015-10-23 | 2024-02-14 | Array Biopharma, Inc. | 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases |
| AU2017342928B2 (en) * | 2016-10-10 | 2021-09-09 | Development Center For Biotechnology | Quinoxaline compounds as type III receptor tyrosine kinase inhibitors |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| JPWO2019189241A1 (ja) | 2018-03-28 | 2021-03-18 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 肝細胞癌治療剤 |
| US11466004B2 (en) | 2018-05-04 | 2022-10-11 | Incyte Corporation | Solid forms of an FGFR inhibitor and processes for preparing the same |
| MA52493A (fr) | 2018-05-04 | 2021-03-10 | Incyte Corp | Sels d'un inhibiteur de fgfr |
| MX2020013757A (es) * | 2018-09-14 | 2021-03-02 | Abbisko Therapeutics Co Ltd | Inhibidor del fgfr, metodo de preparacion y aplicacion del mismo. |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US11680061B2 (en) | 2019-08-08 | 2023-06-20 | Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. | Crystal forms C and E of pyrazin-2(1H)-one compound and preparation method therefor |
| CA3157361A1 (en) | 2019-10-14 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| JP2023505258A (ja) | 2019-12-04 | 2023-02-08 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての三環式複素環 |
| BR112022010664A2 (pt) | 2019-12-04 | 2022-08-16 | Incyte Corp | Derivados de um inibidor de fgfr |
| US20240109865A1 (en) | 2020-12-30 | 2024-04-04 | Tyra Biosciences, Inc. | Indazole compounds as kinase inhibitors |
| IL305178A (en) | 2021-02-26 | 2023-10-01 | Tyra Biosciences Inc | Aminopyrimidine compounds and methods of using them |
| EP4352059A1 (en) | 2021-06-09 | 2024-04-17 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| WO2024006897A1 (en) | 2022-06-29 | 2024-01-04 | Tyra Biosciences, Inc. | Indazole compounds |
| WO2024006883A1 (en) | 2022-06-29 | 2024-01-04 | Tyra Biosciences, Inc. | Polymorphic compounds and uses thereof |
Family Cites Families (108)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2940972A (en) | 1957-06-27 | 1960-06-14 | Thomae Gmbh Dr K | Tri-and tetra-substituted pteridine derivatives |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| GB9125001D0 (en) | 1991-11-25 | 1992-01-22 | Ici Plc | Heterocyclic compounds |
| US5700823A (en) | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
| US6331555B1 (en) | 1995-06-01 | 2001-12-18 | University Of California | Treatment of platelet derived growth factor related disorders such as cancers |
| WO1998004689A1 (en) | 1995-07-31 | 1998-02-05 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
| US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
| TW472045B (en) | 1996-09-25 | 2002-01-11 | Astra Ab | Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation |
| CA2291750A1 (en) | 1997-05-28 | 1998-12-03 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
| UA71555C2 (en) | 1997-10-06 | 2004-12-15 | Zentaris Gmbh | Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives |
| JP2002534512A (ja) | 1999-01-15 | 2002-10-15 | ノボ ノルディスク アクティーゼルスカブ | 非ペプチドｇｌｐ−１アゴニスト |
| US7169778B2 (en) | 1999-09-15 | 2007-01-30 | Warner-Lambert Company | Pteridinones as kinase inhibitors |
| DE10013318A1 (de) | 2000-03-17 | 2001-09-20 | Merck Patent Gmbh | Formulierung enthaltend Chinoxalinderivate |
| WO2002076985A1 (en) | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
| JP4286146B2 (ja) | 2001-12-18 | 2009-06-24 | メルク エンド カムパニー インコーポレーテッド | メタボトロピックグルタミン酸受容体−５のヘテロアリール置換ピラゾール系調節剤 |
| UA82058C2 (uk) | 2001-12-24 | 2008-03-11 | Астразенека Аб | Заміщені похідні хіназоліну як інгібітори ауроракінази, спосіб їх одержання, фармацевтична композиція на їх основі |
| JP2003213463A (ja) | 2002-01-17 | 2003-07-30 | Sumitomo Chem Co Ltd | 金属腐食防止剤および洗浄液 |
| US20040097725A1 (en) | 2002-07-10 | 2004-05-20 | Norman Herron | Charge transport compositions and electronic devices made with such compositions |
| US7825132B2 (en) | 2002-08-23 | 2010-11-02 | Novartis Vaccines And Diagnostics, Inc. | Inhibition of FGFR3 and treatment of multiple myeloma |
| BR0315053A (pt) | 2002-10-03 | 2005-08-09 | Targegen Inc | Agentes vasculostáticos , composição, artigo e processo de preparação dos mesmos |
| AR043059A1 (es) | 2002-11-12 | 2005-07-13 | Bayer Pharmaceuticals Corp | Derivados de indolil pirazinona utiles para el tratamiento de trastornos hiper-proliferativos |
| US7098332B2 (en) | 2002-12-20 | 2006-08-29 | Hoffmann-La Roche Inc. | 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones |
| BRPI0406809A (pt) | 2003-01-17 | 2005-12-27 | Warner Lambert Co | Heterociclos substituìdos de 2-aminopiridina como inibidores da proliferação celular |
| EP1620413A2 (en) | 2003-04-30 | 2006-02-01 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| CN102584813B (zh) | 2003-05-14 | 2016-07-06 | Ngc药物公司 | 化合物及其在调节淀粉样蛋白β中的用途 |
| DE10323345A1 (de) | 2003-05-23 | 2004-12-16 | Zentaris Gmbh | Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren |
| DE502004008322D1 (de) | 2003-05-23 | 2008-12-04 | Aterna Zentaris Gmbh | Neue pyridopyrazine und deren verwendung als modulatoren von kinasen |
| WO2005007099A2 (en) | 2003-07-10 | 2005-01-27 | Imclone Systems Incorporated | Pkb inhibitors as anti-tumor agents |
| EP1646383A4 (en) | 2003-07-21 | 2009-03-25 | Bethesda Pharmaceuticals Inc | DESIGN AND SYNTHESIS OF LIGANDS OPTIMIZED FOR PPAR |
| ATE369862T1 (de) | 2003-10-17 | 2007-09-15 | 4 Aza Ip Nv | Heterocyclus-substituierte pteridin-derivate und ihre verwendung in der therapie |
| WO2005046589A2 (en) | 2003-11-07 | 2005-05-26 | Chiron Corporation | Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties |
| EA009875B1 (ru) | 2003-11-20 | 2008-04-28 | Янссен Фармацевтика Н.В. | 6-алкенил и 6-фенилалкил замещенные 2-хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(адф-рибоза) полимеразы |
| RU2377241C2 (ru) * | 2003-11-24 | 2009-12-27 | Ф.Хоффманн-Ля Рош Аг | Производные пиразоло-имидазопиримидина, обладающие антагонистической активностью в отношении кортикотропин-рилизинг фактора (crf) |
| PL1706385T3 (pl) | 2003-12-23 | 2011-03-31 | Astex Therapeutics Ltd | Pochodne pirazolu jako modulatory kinazy białkowej |
| US7205316B2 (en) | 2004-05-12 | 2007-04-17 | Abbott Laboratories | Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands |
| US7098222B2 (en) | 2004-05-12 | 2006-08-29 | Abbott Laboratories | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents |
| EP1789399A1 (en) | 2004-08-31 | 2007-05-30 | AstraZeneca AB | Quinazolinone derivatives and their use as b-raf inhibitors |
| KR100875408B1 (ko) | 2004-10-14 | 2008-12-23 | 에프. 호프만-라 로슈 아게 | Ｃｄｋ1 항증식성 활성을 갖는 1,5-나프티리딘 아졸리디논 |
| PT1830869E (pt) | 2004-12-24 | 2013-08-22 | Spinifex Pharm Pty Ltd | Método de tratamento ou profilaxia |
| NZ556686A (en) | 2005-02-14 | 2010-01-29 | Bionomics Ltd | Novel tubulin polymerisation inhibitors |
| WO2006092430A1 (de) | 2005-03-03 | 2006-09-08 | Universität des Saarlandes | Selektive hemmstoffe humaner corticoidsynthasen |
| WO2006124354A2 (en) | 2005-05-12 | 2006-11-23 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| CN101223170A (zh) | 2005-05-18 | 2008-07-16 | 惠氏公司 | Tpl2激酶的4,6-二氨基-[1,7]萘啶-3-甲腈抑制剂以及其制备和使用方法 |
| GB0513692D0 (en) | 2005-07-04 | 2005-08-10 | Karobio Ab | Novel pharmaceutical compositions |
| EP1790342A1 (de) | 2005-11-11 | 2007-05-30 | Zentaris GmbH | Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege |
| AU2006313701B2 (en) | 2005-11-11 | 2012-05-31 | Aeterna Zentaris Gmbh | Novel pyridopyrazines and their use as modulators of kinases |
| US8217042B2 (en) | 2005-11-11 | 2012-07-10 | Zentaris Gmbh | Pyridopyrazines and their use as modulators of kinases |
| US8030305B2 (en) | 2005-12-21 | 2011-10-04 | Janssen Pharmaceutica N.V. | Triazolopyridazines as kinase modulators |
| EP2024342A2 (en) | 2006-05-01 | 2009-02-18 | Pfizer Products Incorporated | Substituted 2-amino-fused heterocyclic compounds |
| GB0609621D0 (en) | 2006-05-16 | 2006-06-21 | Astrazeneca Ab | Novel co-crystal |
| JP2009537590A (ja) | 2006-05-24 | 2009-10-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 四員複素環で置換された置換プテリジン |
| US20100016293A1 (en) | 2006-07-03 | 2010-01-21 | Rogier Adriaan Smits | Quinazolines and Related Heterocyclic Compounds, and Their Therapeutic Use |
| JP2008127446A (ja) | 2006-11-20 | 2008-06-05 | Canon Inc | １，５−ナフチリジン化合物及び有機発光素子 |
| JP2010513278A (ja) | 2006-12-13 | 2010-04-30 | シェーリング コーポレイション | Ｉｇｆ１ｒインヒビターを用いた癌の処置方法 |
| CN101641351A (zh) | 2006-12-21 | 2010-02-03 | 普莱希科公司 | 用于激酶调节的化合物和方法及其适应症 |
| CA2672172C (en) * | 2006-12-22 | 2016-05-03 | Astex Therapeutics Limited | Bicyclic heterocyclic compounds as fgfr inhibitors |
| US20100216767A1 (en) | 2006-12-22 | 2010-08-26 | Mina Aikawa | Quinazolines for pdk1 inhibition |
| KR20080062876A (ko) | 2006-12-29 | 2008-07-03 | 주식회사 대웅제약 | 신규한 항진균성 트리아졸 유도체 |
| EP1990342A1 (en) | 2007-05-10 | 2008-11-12 | AEterna Zentaris GmbH | Pyridopyrazine Derivatives, Process of Manufacturing and Uses thereof |
| JP2010526823A (ja) * | 2007-05-10 | 2010-08-05 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | Ｐｉ３キナーゼ阻害物質としてのキノキサリン誘導体 |
| EP2154965A4 (en) | 2007-05-29 | 2011-08-17 | Glaxosmithkline Llc | NAPHTHYRIDINE DERIVATIVES AS P13 KINASE INHIBITORS |
| AR066879A1 (es) | 2007-06-08 | 2009-09-16 | Novartis Ag | Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus |
| US8629144B2 (en) | 2007-06-21 | 2014-01-14 | Janssen Pharmaceutica Nv | Polymorphic and hydrate forms, salts and process for preparing 6-{difluoro[6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}quinoline |
| WO2009019518A1 (en) * | 2007-08-09 | 2009-02-12 | Astrazeneca Ab | Pyrimidine compounds having a fgfr inhibitory effect |
| WO2009021083A1 (en) | 2007-08-09 | 2009-02-12 | Smithkline Beecham Corporation | Quinoxaline derivatives as pi3 kinase inhibitors |
| US20090054304A1 (en) | 2007-08-23 | 2009-02-26 | Kalypsys, Inc. | Heterocyclic modulators of tgr5 for treatment of disease |
| NZ585139A (en) | 2007-11-16 | 2012-05-25 | Incyte Corp | 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as jak inhibitors |
| MX2010012064A (es) | 2008-05-05 | 2010-12-06 | Schering Corp | Uso secuencial de agentes quimioterapeuticos citotoxicos para el tratamiento de cancer. |
| EP2282995B1 (en) | 2008-05-23 | 2015-08-26 | Novartis AG | Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors |
| JP2012509342A (ja) | 2008-11-20 | 2012-04-19 | オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド | 置換ピロロ［２，３−ｂ］−ピリジンおよび−ピラジン |
| JP5662346B2 (ja) | 2009-01-21 | 2015-01-28 | バジリア ファルマスーチカ アーゲーＢａｓｉｌｅａ Ｐｈａｒｍａｃｅｕｔｉｃａ ＡＧ | 新規二環式抗生物質 |
| EP2391623A4 (en) | 2009-02-02 | 2012-09-05 | Merck Sharp & Dohme | INHIBITORS OF AKT ACTIVITY |
| TW201041888A (en) | 2009-05-06 | 2010-12-01 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| WO2010143169A2 (en) | 2009-06-12 | 2010-12-16 | Société Splicos | Compounds useful for treating aids |
| EA021275B9 (ru) | 2009-09-03 | 2015-08-31 | Байоэнердженикс | Гетероциклические соединения, содержащая их фармацевтическая композиция и их применение для лечения pask-опосредованного заболевания |
| CA2772790C (en) | 2009-09-04 | 2017-06-27 | Benjamin Bader | Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors |
| EP2332939A1 (en) | 2009-11-26 | 2011-06-15 | Æterna Zentaris GmbH | Novel Naphthyridine derivatives and the use thereof as kinase inhibitors |
| EP2560966B1 (en) | 2010-03-30 | 2021-01-06 | Verseon International Corporation | Multisubstituted aromatic compounds as inhibitors of thrombin |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| US8513421B2 (en) | 2010-05-19 | 2013-08-20 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
| JP5894980B2 (ja) | 2010-05-24 | 2016-03-30 | インテリカイン， エルエルシー | 複素環式化合物およびその使用 |
| GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
| CN102532141A (zh) | 2010-12-08 | 2012-07-04 | 中国科学院上海药物研究所 | [1，2，4]***并[4，3-b][1，2，4]三嗪类化合物、其制备方法和用途 |
| CN103476777B (zh) | 2011-01-31 | 2015-05-27 | 诺瓦提斯公司 | 新杂环衍生物 |
| AR085397A1 (es) | 2011-02-23 | 2013-09-25 | Intellikine Inc | Combinacion de inhibidores de quinasa y sus usos |
| WO2012118492A1 (en) | 2011-03-01 | 2012-09-07 | Array Biopharma Inc. | Heterocyclic sulfonamides as raf inhibitors |
| WO2013032951A1 (en) | 2011-08-26 | 2013-03-07 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| EP2755657B1 (en) | 2011-09-14 | 2017-11-29 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| US9249110B2 (en) | 2011-09-21 | 2016-02-02 | Neupharma, Inc. | Substituted quinoxalines as B-raf kinase inhibitors |
| US20140235643A1 (en) | 2011-10-04 | 2014-08-21 | Gilead Calistoga Llc | Novel quinoxaline inhibitors of pi3k |
| GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
| JO3210B1 (ar) | 2011-10-28 | 2018-03-08 | Merck Sharp & Dohme | مثبط منصهر لبروتين نقل الكوليسترليستير اوكسازوليدينون ثمائي الحلقة |
| GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| PL2771342T3 (pl) | 2011-10-28 | 2016-11-30 | Nowe pochodne puryny i ich zastosowanie w leczeniu chorób | |
| GB201118652D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| GB201307577D0 (en) | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
| US9221804B2 (en) | 2013-10-15 | 2015-12-29 | Janssen Pharmaceutica Nv | Secondary alcohol quinolinyl modulators of RORγt |
| WO2015144808A1 (en) | 2014-03-26 | 2015-10-01 | Astex Therapeutics Ltd | Combinations of an fgfr inhibitor and an igf1r inhibitor |
| JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
| KR102479693B1 (ko) | 2014-03-26 | 2022-12-22 | 아스텍스 테라퓨틱스 리미티드 | 조합물 |
| JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
-
2010
- 2010-11-29 GB GBGB1020179.6A patent/GB201020179D0/en not_active Ceased
-
2011
- 2011-11-29 US US13/990,193 patent/US9290478B2/en active Active
- 2011-11-29 AU AU2011334624A patent/AU2011334624B2/en active Active
- 2011-11-29 HU HUE11805567A patent/HUE025091T2/en unknown
- 2011-11-29 MX MX2013005897A patent/MX2013005897A/es active IP Right Grant
- 2011-11-29 CA CA2819009A patent/CA2819009C/en active Active
- 2011-11-29 ES ES11805567.2T patent/ES2541493T3/es active Active
- 2011-11-29 DK DK11805567.2T patent/DK2646432T3/en active
- 2011-11-29 EP EP11805567.2A patent/EP2646432B1/en active Active
- 2011-11-29 KR KR1020137016924A patent/KR101914720B1/ko active IP Right Grant
- 2011-11-29 SI SI201130534T patent/SI2646432T1/sl unknown
- 2011-11-29 JP JP2013540440A patent/JP5868992B2/ja active Active
- 2011-11-29 CN CN201180066231.7A patent/CN103370314B/zh active Active
- 2011-11-29 RU RU2013129820/04A patent/RU2602233C2/ru active
- 2011-11-29 WO PCT/GB2011/052356 patent/WO2012073017A1/en active Application Filing
- 2011-11-29 BR BR112013013435-6A patent/BR112013013435B1/pt active IP Right Grant
-
2014
- 2014-01-30 HK HK14101032.2A patent/HK1187916A1/xx unknown
-
2015
- 2015-06-29 HR HRP20150692TT patent/HRP20150692T8/hr unknown
- 2015-08-03 US US14/816,565 patent/US9856236B2/en active Active
- 2015-08-06 SM SM201500191T patent/SMT201500191B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2819009A1 (en) | 2012-06-07 |
| MX2013005897A (es) | 2013-10-25 |
| DK2646432T3 (en) | 2015-07-13 |
| AU2011334624B2 (en) | 2016-09-15 |
| BR112013013435B1 (pt) | 2020-10-20 |
| US20130267525A1 (en) | 2013-10-10 |
| GB201020179D0 (en) | 2011-01-12 |
| BR112013013435A2 (pt) | 2016-10-11 |
| SI2646432T1 (sl) | 2015-08-31 |
| KR101914720B1 (ko) | 2018-11-05 |
| HRP20150692T1 (hr) | 2015-08-14 |
| WO2012073017A1 (en) | 2012-06-07 |
| EP2646432B1 (en) | 2015-04-08 |
| AU2011334624A1 (en) | 2013-06-13 |
| ES2541493T3 (es) | 2015-07-21 |
| US9290478B2 (en) | 2016-03-22 |
| US20160031856A1 (en) | 2016-02-04 |
| CN103370314A (zh) | 2013-10-23 |
| JP5868992B2 (ja) | 2016-02-24 |
| RU2013129820A (ru) | 2015-01-10 |
| KR20130132509A (ko) | 2013-12-04 |
| HRP20150692T8 (en) | 2015-09-25 |
| SMT201500191B (it) | 2015-09-07 |
| JP2013543883A (ja) | 2013-12-09 |
| US9856236B2 (en) | 2018-01-02 |
| CA2819009C (en) | 2020-02-25 |
| EP2646432A1 (en) | 2013-10-09 |
| HUE025091T2 (en) | 2016-01-28 |
| CN103370314B (zh) | 2015-10-21 |
| RU2602233C2 (ru) | 2016-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20150692T8 (en) | Substituted benzopyrazin derivatives as fgfr kinase inhibitors for the treatment of cancer diseases | |
| IL277579A (en) | Piperidinone derivatives as MDM2 inhibitors for cancer therapy | |
| PT3418281T (pt) | Pirazolo[1,5-a]pirimidinas úteis como inibidores da quinase atr para o tratamento de doenças de cancro | |
| ZA201407793B (en) | Treatment of cancer with for tor kinase inhibitors | |
| HK1223832A1 (zh) | 用於癌症治療的激酶抑制劑 | |
| IL215199A0 (en) | Thia-triaza-cyclopentazulenes as pi3-kinases inhibitors for the treatment of cancer | |
| AU2012901199A0 (en) | Kinase inhibitors for the Treatment of Cancer | |
| HK1202118A1 (en) | Piperazinyl derivatives for the treatment of cancer |